

Amendments to the Specification:


On page 1, after the Title, please add the following paragraph:

CROSS-REFERENCE TO RELATED APPLICATIONS

This application is filed pursuant to 35 USC 371 as a United States National Phase Application of International Patent Application Serial No. PCT/US2004/010518 filed on April 6, 2004, which claims priority from 60/462,292 filed on April 11, 2003 in the United States.


On page 2, beginning at line 22, please amend the paragraph as follows:

~~P32897WO1~~ WO03/033480 (GlaxoSmithKline) relates to compounds of the formula



or a salt thereof, wherein M is a group selected from O, S, CO, NH or CH₂, L is a 2 or 3 membered alkylene chain, and the chain -M-L may be optionally substituted by one or more groups selected from methyl, ethyl, hydroxy or alkoxy and or which chain may contain a -C=C- double bond; R₁ and R₂ each independently represent hydrogen, C₁₋₆ straight or branched alkyl which may be optionally substituted by phenyl, or C₃₋₆ cycloalkyl optionally substituted by one or more C₁₋₆ alkyl groups; or R₁ and R₂ together with the nitrogen atom to which they are attached form a 4-8 membered heterocyclic ring or a 7-10 membered bridged heterocyclic ring, which rings may be optionally substituted by a phenyl group or up to 4 C₁₋₃ alkyl groups; or R₁ or R₂ may be linked to the group L or be linked as part of the substituted X on the phenyl ring to form a cyclic group; the group X may be linked to the group L to form a cyclic group which may contain an additional oxygen, a sulphur or nitrogen atom, alternatively or additionally there may be one or more substituents X selected from hydroxy, C₁₋₂ alkyl, C₁₋₂ alkoxy, halogen, C₂₋₃ alkenyl, benzyl, CR_aNOR_b wherein R_a and R_b are independently hydrogen or methyl, methoxy-methyl, methoxymethoxy or methoxyethoxy; QY is a bicyclic fused heterocyclic ring wherein Y is one ring of a

~~P32897WO2~~ WO03/033476 (GlaxoSmithKline) relates to a compound of the formula comprising:



a pharmaceutically acceptable salt or solvate thereof, formulations, processes of preparing, and methods of administering to mammals are provided.